ArticlePCN reports : psychiatry and clinical neurosciences2023
Comparative efficacy and safety of suvorexant and lemborexant for insomnia treatment.
Article in PCN reports : psychiatry and clinical neurosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative efficacy and safety of suvorexant and lemborexant for insomnia treatment.PCN reports : psychiatry and clinical neurosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Although suvorexant and lemborexant, which have orexin receptor antagonist activity, are used as sleep medications in Japan, no report has directly compared their efficacy and safety. This study compared the efficacy and safety of the drugs. Methods: This retrospective cohort study included patients who presented to the Outpatient Department of Psychiatry at Tottori University Hospital between December 1, 2020, and December 31, 2021. Information was obtained from 108 patients who were newly treated with suvorexant or lemborexant. Data were analyzed after excluding one case of discontinuation due to a post-administration allergic reaction. Improvement in sleep status after administration was assessed retrospectively from medical records by using the Clinical Global Impressions-Improvement (CGI-I) Scale, which is a subscale of the Clinical Global Impressions (CGI) Scale. The incidence of side-effects was obtained from the medical records of the patient's first visit after administration. Results: There was no significant difference between the CGI-I scores in the suvorexant (mean [SD], 3.05 [0.93]) and lemborexant groups (mean [SD], 3.38 [0.83]) ( Conclusion: There was no difference in effectiveness between suvorexant and lemborexant. However, lemborexant might cause side-effects less frequently than suvorexant, at least in the early stages of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.